Rein Therapeutics (NASDAQ: RNTX) ends Yorkville advance and equity agreements

Rhea-AI Filing Summary

Rein Therapeutics, Inc. elected to terminate its Pre-Paid Advance Agreement and its Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) on December 11, 2025.

Under the Pre-Paid Advance Agreement, the company had received advances totaling $3 million, with the most recent advance taken on October 23, 2025. The company conducted no sales of its common stock under the Standby Equity Purchase Agreement before termination and reports that no penalties or fees were incurred in connection with ending either arrangement.

Insights

Equity Capital Markets Analyst

Rein Therapeutics ends two Yorkville equity financing arrangements without fees.

On December 11, 2025, Rein Therapeutics elected to terminate its Pre-Paid Advance Agreement and Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville). Under the Pre-Paid Advance Agreement, the company had received advances totaling $3 million, with the most recent advance taken on October 23, 2025. The Standby Equity Purchase Agreement contemplated sales of common stock to Yorkville, but the company conducted no sales of its common stock under that arrangement before termination.

The company states that it incurred no penalties or fees in connection with ending these agreements. This means the two Yorkville financing arrangements are no longer available while the company avoids additional termination costs.

NASDAQ false 0001420565 0001420565 2025-12-11 2025-12-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 11, 2025

REIN THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-38130		13-4196017
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

12407 N. Mopac Expy., Suite 250, #390

Austin, Texas 78758

(Address of principal executive offices)

(737) 802-1989

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock: Par value $.001		RNTX		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.02. Termination of a Material Definitive Agreement.

On December 11, 2025, Rein Therapeutics, Inc. (the “Company”) elected to terminate the Pre-Paid Advance Agreement (the “PPA”) dated July 29, 2025 with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”), and the Standby Equity Purchase Agreement (the “SEPA”) dated July 29, 2025 also entered into with Yorkville. The Company had taken a total of $3 million of advances under the PPA, the most recent advance having been taken on October 23, 2025. The Company conducted no sales of its common stock under the SEPA. No penalties or fees were incurred by the Company in connection with its election to terminate the PPA and SEPA.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				REIN THERAPEUTICS, INC.
Dated: December 11, 2025						/s/ Brian Windsor
						Brian Windsor, Ph.D.,
						President and Chief Executive Officer

FAQ

What financing agreements did Rein Therapeutics (RNTX) terminate on December 11, 2025?

Rein Therapeutics terminated its Pre-Paid Advance Agreement and its Standby Equity Purchase Agreement, both entered into with YA II PN, Ltd. (Yorkville) on July 29, 2025.

How much had Rein Therapeutics drawn under the Pre-Paid Advance Agreement?

The company had taken a total of $3 million of advances under the Pre-Paid Advance Agreement, with the most recent advance made on October 23, 2025.

Did Rein Therapeutics sell any common stock under the Standby Equity Purchase Agreement (SEPA)?

No. Rein Therapeutics conducted no sales of its common stock under the Standby Equity Purchase Agreement before terminating the arrangement.

Were there any penalties or fees associated with terminating the Yorkville agreements?

The company reports that it incurred no penalties or fees in connection with its election to terminate both the Pre-Paid Advance Agreement and the Standby Equity Purchase Agreement.

Who was Rein Therapeutics counterparty for the terminated financing agreements?

Both agreements were with YA II PN, Ltd., a Cayman Islands exempt limited partnership, referred to as Yorkville.